According to an EP Vantage report, analysts' predictions for 2014 sales of the anticoagulant have fallen 60% in the last 12 months. They now stand at $491 million. That is as projections for 2014 sales of Xarelto have surged by 81% and 60% in the respective territories for J&J and Bayer, to $1 billion and $1.4 billion.
Soon to lead a new vaccines, oncology and consumer health division at Pfizer, Schulman says ambitious women need to speak up, spend their political capital and stop asking themselves whether they belong.
Rheumatoid arthritis treatment Xeljanz, while expected to grow into a big seller for Pfizer, hasn't had a fast start. The company hoped adding a psoriasis indication for the drug, also known as tofacitinib, might give sales a jolt. But mixed trial results suggest that approval won't arrive anytime soon--and if it does, demand could be slim.
It seemed like a match made in heaven. A few years ago, as the patent cliff neared and drugmakers were looking for new sources of revenue, market researchers were toting up growth prospects around...
Pfizer set the pace for research shock therapy with an effort that realigned therapeutic priorities, shed programs, shuttered facilities and demanded a much more careful pipeline strategy. But even as the pharma giant has declared the three-year R&D plan at an end, research chief Mikael Dolsten says it's very much a work in progress as the company scrambles to advance the hottest prospects which emerge.
Pharma industry giants have made giant cuts to their workforces over the past several years--about 143,500 jobs were cut by the world's top 11 drugmakers, FirstWord Pharma reports, citing Bloomberg data.
Government shutdown or no, the FDA kept its PDUFA word for Pfizer and Ligand's treatment for hot flashes, approving a long-delayed drug that'll enter the crowded market for hormone therapies.
Pfizer and partner Ligand Pharmaceuticals have gotten a new drug approved to treat hot flashes in some women with menopause.
Currently, patients with autoimmune diseases get transfusions of human intravenous immunoglobulin to bolster their antibody defense system, essential in repelling diseases. But Baltimore-based Gliknik's lead program for GL-2045 is making a bid to do IVIG one better.
Patients who have participated in Pfizer clinical trials will be able to download their data using the 'Blue Button' standard introduced by the White House.